Given as a 2-dose series:1
The second dose can be administered 2 to 6 months after the first dose.
Incorporating SHINGRIX into your practice involves proper administration, discussing disease risk and vaccination, and ensuring series completion.
SHINGRIX is a non-live, recombinant vaccine that is indicated for the prevention of shingles in adults ≥50 years old.1
Refer to the Product Monograph for complete dosing and administration information.
Trademarks are owned by or licensed to the GSK group of companies.
©2021 GSK Group of Companies or its licensor.
PM-CA-SGX-WCNT-210001 | November 2021